Acelyrin (SLRN) News Today → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free SLRN Stock Alerts $4.73 +0.04 (+0.85%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11, 2024 | americanbankingnews.comAcelyrin (SLRN) Scheduled to Post Earnings on MondayMay 9, 2024 | marketwatch.comAcelyrin Founder Steps Down as CEOMay 9, 2024 | msn.comAcelyrin names Mina Kim as new Chief Executive OfficerMay 9, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Price Target Cut to $18.00HC Wainwright dropped their price objective on Acelyrin from $28.00 to $18.00 and set a "buy" rating for the company in a report on Thursday.May 9, 2024 | finance.yahoo.comACELYRIN, INC. Announces Leadership TransitionMay 9, 2024 | globenewswire.comACELYRIN, INC. Provides Business Update and Highlights Key Upcoming MilestonesMay 9, 2024 | americanbankingnews.comAcelyrin, Inc. (NASDAQ:SLRN) Given Average Rating of "Moderate Buy" by BrokeragesMay 6, 2024 | marketbeat.comAcelyrin (SLRN) to Release Earnings on MondayAcelyrin (NASDAQ:SLRN) will be releasing earnings after the market closes on Monday, May 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591359)April 29, 2024 | globenewswire.comACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024April 19, 2024 | marketbeat.comVontobel Holding Ltd. Purchases Shares of 325,549 Acelyrin, Inc. (NASDAQ:SLRN)Vontobel Holding Ltd. acquired a new position in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 325,549 shares of the company's stock, valued at approximately $2,429,000. Vontobel Holding Ltd. owned about 0.3April 17, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Hits New 12-Month Low at $5.10Acelyrin (NASDAQ:SLRN) Sets New 1-Year Low at $5.10April 16, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Down 5.1% Acelyrin (NASDAQ:SLRN) Trading Down 5.1%April 14, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have given a buyApril 10, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Hits New 12-Month Low at $5.61Acelyrin (NASDAQ:SLRN) Sets New 12-Month Low at $5.61April 3, 2024 | marketbeat.comAcelyrin, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.82) Per Share (NASDAQ:SLRN)Acelyrin, Inc. (NASDAQ:SLRN - Free Report) - Research analysts at HC Wainwright issued their Q2 2024 EPS estimates for shares of Acelyrin in a research report issued on Monday, April 1st. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.82) per share for the quarter. HC WainApril 2, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Acelyrin, Inc.'s Q1 2024 Earnings (NASDAQ:SLRN)Acelyrin, Inc. (NASDAQ:SLRN - Free Report) - HC Wainwright issued their Q1 2024 EPS estimates for shares of Acelyrin in a report issued on Monday, April 1st. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.86) per share for the quarter. HC Wainwright currentlyApril 1, 2024 | msn.comStocks Pressured as Bond Yields Jump on Strength in US ManufacturingApril 1, 2024 | markets.businessinsider.comACELYRIN, INC.: Promising Clinical Trials and Market Opportunity Justify Buy RatingApril 1, 2024 | marketbeat.comAcelyrin's (SLRN) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $28.00 target price on shares of Acelyrin in a research note on Monday.March 28, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023March 28, 2024 | finance.yahoo.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMarch 28, 2024 | globenewswire.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMarch 21, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Down 6.3% Acelyrin (NASDAQ:SLRN) Stock Price Down 6.3%March 21, 2024 | marketbeat.comWells Fargo & Company Raises Acelyrin (NASDAQ:SLRN) Price Target to $13.00Wells Fargo & Company raised their price objective on shares of Acelyrin from $11.00 to $13.00 and gave the stock an "equal weight" rating in a report on Thursday.March 20, 2024 | markets.businessinsider.comBuy Rating on ACELYRIN, INC.: Promising Clinical Prospects for Novel TED Therapy LonigutamabMarch 20, 2024 | markets.businessinsider.comAcelyrin Announces Positive Phase 1/2 Data For Lonigutamab In Thyroid Eye Disease; Stock UpMarch 20, 2024 | msn.comInvestors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease PatientsMarch 20, 2024 | finance.yahoo.comACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye DiseaseMarch 20, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Acelyrin, Inc. (NASDAQ:SLRN - Get Free Report) have earned an average rating of "Moderate Buy" from the seven research firms that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendatMarch 20, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Acelyrin (NASDAQ:SLRN)HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Acelyrin in a research report on Wednesday.March 18, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Shares Gap Down to $7.84Acelyrin (NASDAQ:SLRN) Shares Gap Down to $7.84March 18, 2024 | finance.yahoo.comSLRN Apr 2024 2.500 putMarch 15, 2024 | marketbeat.comWalleye Capital LLC Acquires New Stake in Acelyrin, Inc. (NASDAQ:SLRN)Walleye Capital LLC acquired a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 447,355 shares of the company's stock, valued at approximately $4,550,000. Walleye Capital LLC owned approximately 0March 12, 2024 | seekingalpha.comAcelyrin: Analyzing Its Recovery And Potential In Psoriatic ArthritisMarch 12, 2024 | markets.businessinsider.comHold Rating Affirmed for ACELYRIN, INC. as Izokibep Faces Competitive Hurdles and Safety ConcernsMarch 12, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 270,000 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Adage Capital Partners GP L.L.C. lessened its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 73.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,000 shares of the company's stMarch 11, 2024 | marketwatch.comAcelyrin Stock Climbs 10% on Positive Results for Arthritis TreatmentMarch 11, 2024 | msn.comAcelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis StudyMarch 11, 2024 | markets.businessinsider.comAcelyrin's Phase2b/3 Trial Of Izokibep In Psoriatic Arthritis Meets Primary EndpointMarch 11, 2024 | globenewswire.comACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic ArthritisMarch 11, 2024 | globenewswire.comACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for PatientsMarch 8, 2024 | marketbeat.comSchonfeld Strategic Advisors LLC Acquires 147,454 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Schonfeld Strategic Advisors LLC increased its holdings in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 267.1% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 202,662 shares of the company's stock after buying an additional 147,454 shares durMarch 5, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Trading Down 6.9%Acelyrin (NASDAQ:SLRN) Shares Down 6.9%March 3, 2024 | marketbeat.comFred Alger Management LLC Sells 956,843 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Fred Alger Management LLC reduced its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 94.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 53,206 shares of the company's stock after selling 956,843 shares during the period. Fred Alger ManaFebruary 28, 2024 | marketbeat.comAcelyrin, Inc. (NASDAQ:SLRN) Shares Bought by Fmr LLCFmr LLC boosted its position in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 20.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,961,726 shares of the company's stock after buyinFebruary 26, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Trading Up 11.3%Acelyrin (NASDAQ:SLRN) Shares Up 11.3%February 26, 2024 | marketbeat.comEagle Asset Management Inc. Sells 161,687 Shares of Acelyrin, Inc. (NASDAQ:SLRN)Eagle Asset Management Inc. lessened its holdings in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 31.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 358,363 shares of the company's stock after selling 161,687 shFebruary 23, 2024 | marketbeat.comRafferty Asset Management LLC Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN)Rafferty Asset Management LLC purchased a new position in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 173,696 shares of the company's stockFebruary 20, 2024 | marketbeat.comBarclays PLC Takes Position in Acelyrin, Inc. (NASDAQ:SLRN)Barclays PLC bought a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 106,688 shares of the company's stock, valued at approximately $1,084,00February 16, 2024 | marketbeat.comAcelyrin (NASDAQ:SLRN) Trading Up 9%Acelyrin (NASDAQ:SLRN) Stock Price Up 9% Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Bill Clinton Backing Biden Replacement??? (Ad)Bill Clinton is back. And he just met in Mexico with the one person I believe could REPLACE Joe Biden by August… Click here now for my urgent election forecast. SLRN Media Mentions By Week SLRN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLRN News Sentiment▼0.390.56▲Average Medical News Sentiment SLRN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLRN Articles This Week▼104▲SLRN Articles Average Week Get Acelyrin News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TRDA News OCS News ANL News FULC News LXRX News ANNX News LRMR News TVTX News TBPH News CRBP News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLRN) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
